<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="2475"><DrugName>Allervax Cat</DrugName><DrugNamesKey><Name id="42753401">Allervax Cat</Name></DrugNamesKey><DrugSynonyms><Name><Value>Allervax Cat</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Catvax</Value></Name><Name><Value>Fel d 1 peptides, ImmuLogic</Value></Name></DrugSynonyms><CompanyOriginator id="17197">ImmuLogic Pharmaceutical Corp</CompanyOriginator><CompaniesSecondary><Company id="17197">ImmuLogic Pharmaceutical Corp</Company><Company id="25224">Hoechst Marion Roussel Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="2475" type="Drug"><TargetEntity id="219342" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="17197" type="Company"><TargetEntity id="4295906771" type="organizationId">Immulogic Pharmaceutical Corp</TargetEntity></SourceEntity><SourceEntity id="25224" type="Company"><TargetEntity id="4295910625" type="organizationId">Aventis Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="12" type="ciIndication"><TargetEntity id="10001708" type="MEDDRA"></TargetEntity><TargetEntity id="1180" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="12">Allergy</Indication></IndicationsSecondary><ActionsSecondary><Action id="1570">Allergen</Action><Action id="386">Vaccine</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology></Technologies><EphmraCodes><Ephmra><Code>J7</Code><Name>VACCINES</Name></Ephmra></EphmraCodes><LastModificationDate>2017-12-01T14:45:03.000Z</LastModificationDate><ChangeDateLast>2017-02-14T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17197" linkType="Company"&gt;ImmuLogic&lt;/ulink&gt; was developing Allervax Cat for the treatment of allergies to cat dander. In November 1997, however, the company suspended its Allervax Cat and &lt;ulink linkID="8108" linkType="Drug"&gt;Allervax Ragweed&lt;/ulink&gt; clinical programs in order to concentrate on its other vaccine programs [&lt;ulink linkID="270247" linkType="reference"&gt;270247&lt;/ulink&gt;]. The program has subsequently been discontinued [&lt;ulink linkID="315441" linkType="reference"&gt;315441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002, it was reported that the delivery of two Fel d 1 (cat allergen)-derived 27-amino acid peptides to patients at quadruple doses of 7.5, 75 and 750 mg sc, with a weekly dose interval, led to considerable early and late adverse events, including chest tightness, wheezing, allergies and asthma [&lt;ulink linkID="448626" linkType="reference"&gt;448626&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;ImmuLogic began patient screening for the phase III, placebo-controlled trial in the US in April 1995. The trial included approximately 270 patients [&lt;ulink linkID="190579" linkType="reference"&gt;190579&lt;/ulink&gt;], [&lt;ulink linkID="184122" linkType="reference"&gt;184122&lt;/ulink&gt;], and positive results were announced in April 1996. Patients in the most intensive treatment group (750 microg dose two times a week for two weeks) experienced a statistically significant (p = 0.01) improvement in total allergy symptom scores, the primary endpoint of the study, compared with placebo recipients [&lt;ulink linkID="206328" linkType="reference"&gt;206328&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 1996, the phase III trial was completed and ImmuLogic met with the FDA to discuss the development schedule for Allervax Cat. &lt;/para&gt;&lt;para&gt;According to a joint study by researchers at Johns Hopkins and the &lt;ulink linkID="18507" linkType="Company"&gt;New England Medical Center&lt;/ulink&gt;, Allervax Cat reduces allergy symptoms faster, and with fewer injections, than traditional allergy shots. The research team gave 95 cat allergic patients four injections of various levels of the vaccine or a placebo, followed by exposure to a room containing cats. The vaccine significantly reduced sneezing, itching, watery eyes and inflammation after a month of treatment [&lt;ulink linkID="228911" linkType="reference"&gt;228911&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase II cat room study, 86% of patients in the 750 microg dose group showed symptomatic improvement on exposure to cats relative to pretreatment. In the bronchial challenge trial, 71% of patients in the group were able to tolerate more cat allergen after treatment. Side effects were mild and transient [&lt;ulink linkID="177686" linkType="reference"&gt;177686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;This family of allergy therapeutics, including &lt;ulink linkID="8108" linkType="Drug"&gt;Allervax Ragweed&lt;/ulink&gt;, were being developed with Hoechst Marion Roussel, but this agreement was terminated in March 1996 [&lt;ulink linkID="201048" linkType="reference"&gt;201048&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A variety of vaccines have been produced to the cloned antigens of allergens involved in common allergies. Included are vaccines against cats (Allervax Cat), house mites (Allervax mite), ragweed pollen (Allervax Ragvax) and grass pollen (Allervax grass). The vaccines work by blocking the immune response to allergen [&lt;ulink linkID="52001" linkType="reference"&gt;52001&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Dr David Chantry, ICOS Corporation, Bothell, WA, USA&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;18 March 1997&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Cat allergy is caused, principally, by an immune response directed against the protein Fel dI which is present in cat epithelium and saliva. Fel dI was cloned [&lt;ulink linkType="reference" linkID="239155"&gt;239155&lt;/ulink&gt;] and the epitopes recognized by T-cell lines from cat-sensitive patients mapped [&lt;ulink linkType="reference" linkID="239166"&gt;239166&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt; comprises two synthetic 27 amino acid peptides derived from Fel dI. These peptides encompass the majority of the epitopes recognized by Fel dI reactive T-cells from allergic individuals [&lt;ulink linkType="reference" linkID="239166"&gt;239166&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;No data are reported.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;No data are reported. The optimum dosing has been determined empirically based on clinical efficacy. Current trial data indicate that treatment will be subcutaneous administration of 750 microg of &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt; twice-weekly for two weeks [&lt;ulink linkType="reference" linkID="206328"&gt;206328&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;Data from clinical trials indicate that &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt; is well tolerated [&lt;ulink linkType="reference" linkID="239168"&gt;239168&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="233123"&gt;233123&lt;/ulink&gt;]. Mild and transient side-effects have been reported in approximately one-third of patients.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;The reported side effects included minor respiratory symptoms (chest tightness), runny nose and itching skin (without hives) [&lt;ulink linkType="reference" linkID="233123"&gt;233123&lt;/ulink&gt;]. These symptoms compare favorably with current immunotherapy for allergic disease (using cat pelt extracts) where there is the risk of IgE-induced side-effects including systemic anaphylaxis.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt; was generally well-tolerated at doses up to 1.5 mg [&lt;ulink linkType="reference" linkID="239166"&gt;239166&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In a placebo-controlled, double-blind trial, 95 cat-allergic asthmatic subjects were exposed to cat allergen ('cat room' exposure) before or after treatment with &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt; (7.5 microg, 75 microg or 750 microg) weekly for four weeks [&lt;ulink linkType="reference" linkID="233123"&gt;233123&lt;/ulink&gt;]. A statistically significant reduction in symptoms was observed six weeks after treatment with 75 microg or 750 microg of &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt;In a second phase II trial, 72 cat-allergic asthmatic subjects were subjected to direct bronchial challenge with allergen following treatment with &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt; (750 microg, weekly for four weeks, or escalating doses beginning at 25 microg) [&lt;ulink linkType="reference" linkID="233126"&gt;233126&lt;/ulink&gt;]. The 750 microg group showed a statistically significant benefit, as measured by the amount of allergen required to drop forced expiratory volume at one second by 20%, when compared to the placebo or dose escalation group [&lt;ulink linkType="reference" linkID="233126"&gt;233126&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;270 Patients were included in the placebo-controlled, double-blind trial [&lt;ulink linkType="reference" linkID="206328"&gt;206328&lt;/ulink&gt;]. Subjects were exposed to allergen challenge in a 'cat room' before and after treatment with &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt; (750 microg, twice-weekly for two weeks, 750 microg, once a week for four weeks, 75 microg, twice-weekly for two weeks or 75 microg, once a week for four weeks). A statistically significant (p &amp;lt; 0.01) improvement in total symptoms was obtained in the most aggressive treatment group (750 microg of &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt;, twice-weekly for two weeks) compared to placebo control. Immunolgic plans to initiate a further phase II/III trial in the second quarter of 1997 and at least one more confirmatory trial is expected prior to filing of the PLA [&lt;ulink linkType="reference" linkID="229104"&gt;229104&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;The ability to induce tolerance to protein antigens is based on well-established immunological principles. This approach is particularly attractive for the treatment of cat allergy where the allergen has been well defined. &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt; is used to induce tolerance in the T-cells of allergic individuals to the allergen Fel dI. In the absence of T-cell responses, B-cells fail to respond to the allergen and IgE production is blocked. Elevation in IgE is a major activation signal for mast cells which produce the key mediators of the allergic response, such as histamine, thus the blockade of IgE prevents this allergic response. The efficacy of this approach was initially demonstrated in preclinical animal studies [&lt;ulink linkType="reference" linkID="239170"&gt;239170&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Current clinical trial data are encouraging and the lack of severe allergic responses to &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt; represents a clear improvement over currently available therapy. In the most recent (phase III) trial, &lt;ulink linkType="Drug" linkID="2475"&gt;Allervax Cat&lt;/ulink&gt;-treated individuals showed a statistically significant improvement in their symptoms compared to the placebo group [&lt;ulink linkType="reference" linkID="206328"&gt;206328&lt;/ulink&gt;]. These results were, however, only obtained in the highest dose group. Moreover this is a novel dosing regiment for Immunolgic and this has led to a delay in clinical development. Immunolgic therefore, plans to initiate another phase II/III trial in the second quarter of 1997 and a further confirmatory trial is expected prior to filing of the PLA [&lt;ulink linkType="reference" linkID="229104"&gt;229104&lt;/ulink&gt;]. &lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="12">Allergy</Indication><StatusDate>1996-03-01T00:00:00.000Z</StatusDate><Source id="201048" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17197">ImmuLogic Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="12">Allergy</Indication><StatusDate>1999-02-25T00:00:00.000Z</StatusDate><Source id="315441" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17197">ImmuLogic Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>1997-11-25T00:00:00.000Z</StatusDate><Source id="270247" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17197">ImmuLogic Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><Source id="176873" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17197">ImmuLogic Pharmaceutical Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="121367" title="Marion Marrel Dow to develop ImmuLogic's Allervax products                "/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>